Collateral for a security interest recorded Oct 20, 2025 (Biopharma Credit PLC).
Term ends Mar 14, 2033 · High confidence
20-year base term ends Mar 14, 2033
Held by Valneva Austria GmbH
Filed Dec 4, 2019 as application 16/702,885 · Granted Oct 11, 2022
Base term, 20 years from filing
Today
2013
2033
Clock starts
Mar 14, 2013
Mar 14, 2013
Term ends
Mar 14, 2033
Mar 14, 2033
Granted
Oct 11, 2022
Oct 11, 2022
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 10,544,194, US 10,766,931, US 11,208,439, US 8,986,704, US 9,975,927, to Mar 14, 2033. The term already ends on or before that date, so the cap shortened nothing.
1 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
10
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 2 maintenance fees is paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Mar 14, 2013, when application 13/802,991, the earliest non-provisional in its chain, was filed (this one was filed Dec 4, 2019) | Mar 14, 2033 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,544,194, US 10,766,931, US 11,208,439, US 8,986,704, US 9,975,927) | resolves to Mar 14, 2033, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Mar 14, 2033 | High confidence |
This family
| US 8,986,704 | In force Mar 2033 | Mar 2033 |
| Application 14/412,722 | Abandoned not computed | not computed |
| Application 14/623,681 | Abandoned not computed | not computed |
| US 9,926,343 | In force Mar 2033 | Mar 2033 |
| US 10,544,194 | In force Mar 2033 | Mar 2033 |
| US 11,208,439 | In force Mar 2033 | Mar 2033 |
| US 11,466,058 | this patent Mar 2033 | Mar 2033 |
| US 12,195,501 | In force Mar 2033 | Mar 2033 |
8 of 10 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Mar 4, 2020 Reel 52016, frame 745 | Valneva SE; Valneva USA, Inc.; Valneva Austria GmbH | Wilmington Trust, National Association | Security Interest |
| Dec 7, 2020 Reel 54563, frame 420 | Comstedt, Pär; Lundberg, Urban; Meinke, Andreas; Hanner, Markus; Schüler, Wolfgang; Wizel, Benjamin; Reinisch, Christoph; Grohmann, Brigitte; Schlegl, Robert | Valneva Austria GmbH | Assignment of Assignor's Interest |
| Oct 20, 2025 Reel 73164, frame 32 | Valneva Austria GmbH; Valneva SE; Valneva Sweden AB | Biopharma Credit PLC, as Collateral Agent | Patent Security Agreement |
| Nov 10, 2025 Reel 73516, frame 522 | Wilmington Trust, National Association, as Administrative Agent | Valneva Austria GmbH; Valneva SE; Valneva USA, Inc. | Release of Security Interest |
| Nov 10, 2025 reel/frame not recorded | Wilmington Trust, National Association, as Administrative Agent | Valneva Austria GmbH | Release of Security Interest |
| Nov 10, 2025 reel/frame not recorded | Wilmington Trust, National Association, as Administrative Agent | Valneva SE | Release of Security Interest |
| Nov 10, 2025 reel/frame not recorded | Wilmington Trust, National Association, as Administrative Agent | Valneva USA, Inc. | Release of Security Interest |
| Mar 31, 2026 Reel 75335, frame 609 | Valneva Austria GmbH; Valneva SE; Valneva Sweden AB | Biopharma Credit PLC, as Collateral Agent | Amended and Restated Patent Security Agreement |
| Jun 4, 2026 Reel 75803, frame 558 | Valneva Austria GmbH; Valneva SE; Valneva Sweden AB | Biopharma Credit PLC, as Collateral Agent | Amended and Restated Patent Security Agreement |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Mar 2033
Term ends Mar 14, 2033. Maintenance fees still fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 10,544,194, US 10,766,931, US 11,208,439, US 8,986,704, US 9,975,927, ends no earlier than this term, so it caps nothing.
Citations
8
later US patents cite this one
That is top 25% of utility patents granted in 2022 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.